Moringa Acquisition Corp: Nasdaq/NYSE listing notice — Moringa Acquisition Corp receives Nasdaq delisting notice for failure to complete business combination within 36 months

Moringa Acquisition Corp

Received delisting notice on Feb 20, 2024; trading would be suspended Feb 29 unless hearing requested.
Non-compliance with Nasdaq IM-5101-2 requiring SPAC business combination within 36 months of IPO.
Company will request hearing to stay suspension pending completion of proposed combination with Silexion Therapeutics.
No assurance Nasdaq will grant relief or that business combination will be completed.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Moringa Acquisition Corp received a nasdaq delisting notice notice regarding other (rules IM-5101-2).

Exchange: nasdaq
Notice: delisting notice
Rules: IM-5101-2

Exact text from the filing

February 20, 2024, Moringa Acquisition Corp, a Cayman Islands exempted company (the “ Company ”) received a notice from the staff of the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “ Panel ”), trading of the Company’s securities on The Nasdaq Capital Market would be suspended at the opening of business on February 29, 2024, due to the Company’s non-compliance with Nasdaq IM-5101-2, which requires that a special purpose acquisition company complete one or more bus

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001213900-24-016968

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.